Enoximone is a synthetic phosphodiesterase III (PDE3) inhibitor that has been investigated and used as an inotropic and vasodilator agent in cardiovascular applications. By inhibiting PDE3, Enoximone increases intracellular cyclic AMP (cAMP), producing positive inotropic and vasodilatory effects.
Enoximone is a small-molecule pharmaceutical compound belonging to the imidazolone derivative class.
Enoximone is a selective PDE3 inhibitor developed for cardiovascular applications, particularly in conditions where increased cardiac contractility and reduced vascular resistance may be beneficial.
It has the molecular formula C₁₂H₁₇N₃O₃ and a molecular weight of approximately 251.28 g/mol.
Swapnroop Drugs and Pharmaceuticals provides Enoximone API for qualified pharmaceutical manufacturing, formulation development, research and pharmaceutical sourcing requirements.
Enoximone is a specialized cardiovascular pharmaceutical ingredient associated with PDE3 inhibitor drug development.
Enoximone inhibits phosphodiesterase III, an enzyme responsible for the breakdown of cyclic AMP. PDE3 inhibition increases intracellular cAMP in cardiac and vascular smooth-muscle cells.
This results in:
Enoximone is associated with:
| Parameter | Specification |
|---|---|
| Appearance | White to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.5% |
| Heavy Metals | NMT 20 ppm |
| pH (1% Solution) | 2.0 – 4.0 |
| Individual Impurity | NMT 0.5% |
| Total Impurities | NMT 1.0% |
| Water Content | NMT 1.0% |
| Melting Point | 150°C – 154°C |